Oncology

Back to articles

Aromatase inhibitors increasingly important in breast cancer care

KEY POINT

A miracle drug in its own time, tamoxifen is increasingly being replaced by aromatase inhibitors in adjuvant postsurgical management of breast cancer. Drug such as letrozole (Femara—Novartis), exemestane (Aromasin— Pfizer), and anastrozole (Arimidex—AstraZeneca) provide increased efficacy but also produce a different set of adverse effects, compared with tamoxifen.